Recital 35, Regulation (EU) 2026/2348

In force

Two applications for the renewal of the approval of the active substance sulcotrione were submitted on 27 July and 29 August 2016, respectively, and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 25 October 2016 that it had assessed the admissibility of the applications pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular their completeness and timeliness, and concluded that they were admissible. The applications have been made public by the Authority. On 24 August 2022, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 19 February and 19 April 2024. On 5 February 2025, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicants submitted that information on 5 March 2025 within the deadline given. The Authority estimates that it will be able to finalise its conclusion for sulcotrione by the end of April 2027, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 20 months and 15 days, until 15 August 2028.

  • celex=32012R0844